SEXUAL HEALTH · PEPTIDE
What is PT-141?
Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026
THE SHORT ANSWER
PT-141 is the research name for bremelanotide, a peptide that acts on melanocortin receptors in the brain to increase sexual desire. It is FDA-approved as Vyleesi for low sexual desire in premenopausal women and is injected as needed.
PT-141 at a glance
- Type
- Peptide
- Also known as
- Bremelanotide, Vyleesi
- Mechanism
- Melanocortin receptor agonist (bremelanotide)
- Status
- FDA-approved
- Half-life
- ~2.7 hours
- Route
- Subcutaneous
- Dosing range in the literature
- 0.5–1.75 mg as needed
- Onset
- 45–60 minutes
- Storage
- Refrigerated (2–8 °C); use within the pharmacy beyond-use date
How PT-141 works
It activates melanocortin receptors in brain regions involved in sexual motivation. Unlike drugs such as sildenafil, it works on desire in the brain, not on blood flow.
What PT-141 is studied for
- Sexual desire
- Arousal
Two phase 3 trials in premenopausal women showed modest improvements in desire and reductions in related distress. Nausea was common. Use in men is off-label and less studied.
Being studied for something is not proof that it works. Results in individuals vary.
PT-141 dosing
Published protocols describe 0.5–1.75 mg as needed, as needed; max 1 per 24 h, 8 per month, given subcutaneous. Onset is typically reported at 45–60 minutes.
These figures are context from the literature, not instructions. A licensed provider sets the dose and schedule for each patient.
PT-141 side effects and risks
- Nausea
- Flushing
- Transient blood-pressure rise
- Headache
Tell your provider about every medication and condition before starting, and report anything unexpected. See peptide side effects and safety and who should not use peptides.
Is PT-141 FDA approved?
FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Other uses are off-label.
Approval and trial status change. This page was last reviewed on October 1, 2026.
PT-141 at G1 Peptides
G1 Peptides supplies PT-141 as vials (10 mg, 20 mg) and in pens (Ares X). Prescription products ship only after a licensed provider has reviewed the order.
PT-141 questions
- What is PT-141?
- PT-141 is the research name for bremelanotide, a peptide that acts on melanocortin receptors in the brain to increase sexual desire. It is FDA-approved as Vyleesi for low sexual desire in premenopausal women and is injected as needed.
- What is PT-141 used for?
- PT-141 is studied for sexual desire and arousal. Two phase 3 trials in premenopausal women showed modest improvements in desire and reductions in related distress. Nausea was common. Use in men is off-label and less studied.
- How does PT-141 work?
- It activates melanocortin receptors in brain regions involved in sexual motivation. Unlike drugs such as sildenafil, it works on desire in the brain, not on blood flow.
- Is PT-141 FDA approved?
- FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Other uses are off-label.
- What is the typical PT-141 dosage?
- Published protocols describe 0.5–1.75 mg as needed, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.
- What are the side effects of PT-141?
- Risks noted for PT-141 include nausea, flushing, transient blood-pressure rise, and headache. Tell your provider about your medications and conditions before starting.
- What is the half-life of PT-141?
- The reported half-life is ~2.7 hours. Onset is typically reported at 45–60 minutes.
- How should PT-141 be stored?
- Refrigerated (2–8 °C); use within the pharmacy beyond-use date.
For educational purposes only, and not medical advice. These statements have not been evaluated by the FDA. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease. Use any compound only under the guidance of a licensed provider.